Michael Barbella, Managing Editor05.21.22
MPO website visitors followed the money this past week. Literally.
Investments and acquisitions most influenced site traffic, led by news of Medtronic completing the approximately $1 billion deal for ear, nose, and throat firm Intersect ENT. Begun last August, the transaction gives Medtronic ENT's Propel and Sinuva sinus implant product lines and expands its portfolio to include products used in sinus procedures that improve post-op outcomes and treat nasal polyps. Former Intersect ENT brand Fiagon was divested at the deal’s close, not included in the acquisition terms.
Also generating page views was Medical Manufacturing Technologies' (MMT) purchase of Medical Production Technology Europe (MPT), Brainlab's majority acquisition of medPhoton, and GE Healthcare's investment in Pulsenmore.
The MMT-MPT union expands the former's catheter manufacturing solutions offering; MPT provides equipment and process development services centered on balloon forming, folding and pleating, thermal bonding, and stent crimping solutions.
Brainlab's majority acquisition of Austria-based medPhoton, developer and manufacturer of robotic imaging for image-guided radiation therapy and surgery, will enable both firms to "shape the future" of intraoperative imaging. The companies have partnered in the intraoperative imaging field, resulting in the launch of the Loop-X mobile imaging robot in 2020. medPhoton will operate as an independent R&D firm within Brainlab, and together the companies will explore options in brachytherapy, particle therapy, and intra-op radiation therapy. The pair also will further grow capabilities at medPhoton's Salzburg, Austria, site.
GE Healthcare is investing up to $50 million in Israeli startup Pulsenmore, a developer of homecare ultrasound solutions. The investment aims to help Pulsenmore pursue U.S. Food and Drug Administration clearance and commercial growth. GE will also help distribute the company’s products in Europe and other markets as the product becomes available. Pulsenmore’s self-operated prenatal home ultrasound combines with a smartphone to help pregnant women self-scan for remote clinical assessment. The offering includes a handheld ultrasound that docks with the user’s smartphone, a mobile app for consultation, a web application for clinician interaction, and a software API for integration of online services with health records. The periodic fetal ultrasound scanning and consultation can be offered as a clinician-guided telecom service or offline, application-guided service.
Investments and acquisitions most influenced site traffic, led by news of Medtronic completing the approximately $1 billion deal for ear, nose, and throat firm Intersect ENT. Begun last August, the transaction gives Medtronic ENT's Propel and Sinuva sinus implant product lines and expands its portfolio to include products used in sinus procedures that improve post-op outcomes and treat nasal polyps. Former Intersect ENT brand Fiagon was divested at the deal’s close, not included in the acquisition terms.
Also generating page views was Medical Manufacturing Technologies' (MMT) purchase of Medical Production Technology Europe (MPT), Brainlab's majority acquisition of medPhoton, and GE Healthcare's investment in Pulsenmore.
The MMT-MPT union expands the former's catheter manufacturing solutions offering; MPT provides equipment and process development services centered on balloon forming, folding and pleating, thermal bonding, and stent crimping solutions.
Brainlab's majority acquisition of Austria-based medPhoton, developer and manufacturer of robotic imaging for image-guided radiation therapy and surgery, will enable both firms to "shape the future" of intraoperative imaging. The companies have partnered in the intraoperative imaging field, resulting in the launch of the Loop-X mobile imaging robot in 2020. medPhoton will operate as an independent R&D firm within Brainlab, and together the companies will explore options in brachytherapy, particle therapy, and intra-op radiation therapy. The pair also will further grow capabilities at medPhoton's Salzburg, Austria, site.
GE Healthcare is investing up to $50 million in Israeli startup Pulsenmore, a developer of homecare ultrasound solutions. The investment aims to help Pulsenmore pursue U.S. Food and Drug Administration clearance and commercial growth. GE will also help distribute the company’s products in Europe and other markets as the product becomes available. Pulsenmore’s self-operated prenatal home ultrasound combines with a smartphone to help pregnant women self-scan for remote clinical assessment. The offering includes a handheld ultrasound that docks with the user’s smartphone, a mobile app for consultation, a web application for clinician interaction, and a software API for integration of online services with health records. The periodic fetal ultrasound scanning and consultation can be offered as a clinician-guided telecom service or offline, application-guided service.
